Catalyst Event
Merck and Co Inc (MRK) · Other
From Akros U.S. Tech 100 Index (AUT100)
4/13/2026, 12:00:00 AM
The U.S. FDA granted Priority Review for the Biologics License Application for ifinatamab deruxtecan for a type of small cell lung cancer on April 13, 2026. The PDUFA action date is set for October 10, 2026.
Korean Translation
미국 FDA, 2026년 4월 13일 소세포폐암 치료제 이피나타맙 데룩스테칸의 생물의약품 허가 신청에 대한 우선 심사를 승인함. 처방의약품 신청자 수수료법(PDUFA)에 따른 결정일은 2026년 10월 10일임.
Related Recent Events
Cloudflare Inc (NET) · Other
Cloudflare is scheduled to host an Investor Day on June 9, 2026; a >=5% price impact is estimated as the company provides strategic updates scheduled.
6/9/2026, 12:00:00 AM
Medtronic PLC (MDT) · Earnings Release
Medtronic will report its financial results for the fourth quarter and full fiscal year 2026 on June 3, 2026 (High importance estimated due to potential volatility from annual results), scheduled.
6/3/2026, 12:00:00 AM
Hewlett Packard Enterprise Co (HPE) · Earnings Release
Q2 2026 earnings release is scheduled.
6/2/2026, 12:00:00 AM
Marvell Technology Inc (MRVL) · Earnings Release
First quarter fiscal year 2027 earnings results are scheduled to be released on May 29, 2026. Market impact is estimated at >1% as earnings releases typically drive volatility scheduled.
5/29/2026, 12:00:00 AM
Analog Devices Inc (ADI) · Earnings Release
Analog Devices is expected to release its fiscal second quarter 2026 financial results around late May. The date is estimated based on previous reporting schedules and is scheduled.
5/28/2026, 12:00:00 AM
Axon Enterprise Inc (AXON) · Other
Axon's Annual Meeting of Shareholders on 2026-05-28 where director Matthew McBrady will not seek re-election, which is estimated to have low importance as board changes are common, is scheduled.
5/28/2026, 12:00:00 AM